Sino Biopharmaceutical Limited (1177.HK)
Develops and sells cancer, liver disease, and respiratory medicines in China
5.18+0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago-29.2%
The outlook
Sino Biopharmaceutical has strong analyst backing with an average "Strong Buy" rating, and the consensus price target sits about 57% above the current level. The stock is trading near its 52-week low, though its price action relative to moving averages shows mixed momentum. A trailing P/E of 34.5 reflects elevated valuation relative to earnings.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 20 analysts
Price trendMixed vs its moving averages
52-week range20% of the way from its 52-week low to high
Price targetAvg target +57% vs current price
Analyst price target
~12-month · 20 analysts8.12average target+56.8% vs now
Now 5.18
Low 5.60High 10.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$92.07B
52-wk high
9.12
52-wk low
4.19
50-day avg
4.87
200-day avg
6.05
Trailing P/E
34.5